Webcast: EDAP Presentation at Roth Capital Conference EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, presented at the Roth Capital Partners New York Conference on September 6, 2006 at the Westin Time Square Hotel in New

Vanderbilt-Ingram Cancer Center recently issued the following press release announcing its participation in the US Clinical Trial Study of the Ablatherm-HIFU device from EDAP.

Increasing Sites and Utilization Rate Necessitates Third Unit; Market More Than Double Prior Year

Recent US News & World Report Feature Highlights HIFU as Future of Prostate Cancer Therapy A recent article found in US News & World Report highlights HIFU and robotic surgery as key treatments of the future in the fight against early stage prostate cancer.

Study to Appear in June 2011 Current Urology Report

LYON, France , Nov. 24, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced data from a multicenter trial demonstrating encouraging outcomes of focal HIFU as a new treatment strategy for patients with unilateral localized prostate cancer.

Paris Match Article We are excited to announce that the widely read French public magazine Paris-Match has featured an interview with Professor Guy Vallancien, head of the urology department at the Institut [of] Mutualiste Montsouris Paris. Professor Vallancien is the leading pioneer of robotic

The following article appeared September 27, 2006 in WRAL.com serving the Raleigh-Durham & Fayetteville, North Carolina areas. The story can be viewed at http://www.wral.com/health/9947426/detail.html. Ultrasound Waves Being Used To Treat Prostate Cancer

First UK Fixed Revenue-Per-Procedure Service Available at Capio Springfield Hospital

Continued Interest from Leading Urologists; Growing Treatment Activity and Referrals